Skip to main content

Drug Interactions between deuruxolitinib and Tarceva

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

erlotinib deuruxolitinib

Applies to: Tarceva (erlotinib) and deuruxolitinib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of erlotinib with anti-angiogenic agents, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or taxane-based chemotherapy may increase the risk of gastrointestinal (GI) perforation. Erlotinib treatment has been associated with an increased risk of developing gastrointestinal (GI) perforation, including fatal cases. Patients with a prior history of peptic ulceration or diverticular disease may also have an increased risk. In three lung cancer studies with erlotinib monotherapy and a pancreatic cancer study with erlotinib plus gemcitabine, the incidence of gastrointestinal perforation in patients treated with erlotinib was 0.2% and 0.4%, respectively, compared to 0.1% and 0% in the control arms. Cases of GI bleeding have also been reported with concomitant administration of NSAIDs.

MANAGEMENT: Caution is recommended when using erlotinib in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as anti-angiogenic agents, corticosteroids, NSAIDs, and taxane-based chemotherapy. Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting. The manufacturer recommends that erlotinib should be permanently discontinued in patients who develop gastrointestinal perforation.

Drug and food/lifestyle interactions

Moderate

erlotinib food/lifestyle

Applies to: Tarceva (erlotinib)

Erlotinib should be taken on an empty stomach at least 1 hour before or 2 hours after a meal and at the same time each day unless otherwise directed by your doctor. You should also avoid grapefruit and grapefruit juice while taking erlotinib. Food and grapefruit juice can increase the absorption of erlotinib from the gastrointestinal tract, which may lead to higher blood levels of the medication and possibly increased side effects. If you are a smoker, you should try to quit as soon as you can. Cigarette smoking can reduce the blood levels of erlotinib, which may make the medication less effective in treating your cancer. It is best to avoid smoking during erlotinib therapy. Talk to a healthcare professional if you have any questions or concerns. If you start smoking or undergo smoking cessation, your doctor may need to adjust your dose of erlotinib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

deuruxolitinib food/lifestyle

Applies to: deuruxolitinib

Consumer information for this interaction is not currently available.

MONITOR: Smoking during treatment with deuruxolitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies. In clinical studies of deuruxolitinib, individuals who were current or former smokers had an additional increased risk of overall malignancies. Also, deuruxolitinib may increase patients' risk of MACE, including myocardial infarction, stroke, and cardiovascular death.

MANAGEMENT: Caution is advised if deuruxolitinib is prescribed to current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing deuruxolitinib in patients that have experienced a myocardial infarction or stroke. Deuruxolitinib may be taken with or without food.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.